Market closed

vTv Therapeutics/$VTVT

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About vTv Therapeutics

vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.

Ticker

$VTVT

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

High Point, United States

Employees

Website

vtvtherapeutics.com

vTv Therapeutics Metrics

BasicAdvanced

$35M

-

-$7.01

0.66 -

Price and volume

Market cap

$35M

Beta

0.66

52-week high

$30.99

52-week low

$7.38

Average daily volume

21K

Financial strength

Current ratio

6.687

Quick ratio

6.522

Long term debt to equity

0.179

Total debt to equity

1.189

Interest coverage (TTM)

-3,427.86%

Management effectiveness

Return on assets (TTM)

-51.64%

Return on equity (TTM)

-1,335.04%

Valuation

Price to revenue (TTM)

35.135

Price to book

2.34

Price to tangible book (TTM)

2.34

Price to free cash flow (TTM)

-1.502

Growth

Revenue change (TTM)

11,011.11%

Earnings per share change (TTM)

-30.91%

3-year revenue growth (CAGR)

-54.18%

3-year earnings per share growth (CAGR)

27.45%

What the Analysts think about vTv Therapeutics

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for vTv Therapeutics stock.

vTv Therapeutics Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

vTv Therapeutics Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

vTv Therapeutics News

AllArticlesVideos

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

GlobeNewsWire·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VTVT

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for vTv Therapeutics stock?

vTv Therapeutics (VTVT) has a market cap of $35M as of January 15, 2025.

What is the P/E ratio for vTv Therapeutics stock?

The price to earnings (P/E) ratio for vTv Therapeutics (VTVT) stock is 0 as of January 15, 2025.

Does vTv Therapeutics stock pay dividends?

No, vTv Therapeutics (VTVT) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next vTv Therapeutics dividend payment date?

vTv Therapeutics (VTVT) stock does not pay dividends to its shareholders.

What is the beta indicator for vTv Therapeutics?

vTv Therapeutics (VTVT) has a beta rating of 0.66. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.